January 21, 2015.
More than 80 pharma companies and organizations have called on industry and governments worldwide for action to combat drug-resistant infections.
The top ten pharma companies are among those that have signed the Declaration on Combating Antimicrobial Resistance (AMR), announced at the World Economic Forum in Davos, Switzerland. The declaration outlines how industry and governments can work together to support sustained innovation to address the growing problem of AMR.
The independent UK
Review on Antimicrobial Resistanceestimates that without effective global action, the rise of drug-resistant infections could claim 10 million lives globally each year by 2050 and result in a cumulative loss from global output of 100 trillion USD. The Declaration outlines three areas in which the companies will work to prevent and treat drug-resistant infections: reduce drug resistance through appropriate use of new and existing antibiotics; increase investment and collaboration in research and development; and improve access to high-quality antibiotics.
http://amr-review.org/industry-declaration
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.